ES2745208T3 - Nanoestructuras para tratar cánceres - Google Patents

Nanoestructuras para tratar cánceres Download PDF

Info

Publication number
ES2745208T3
ES2745208T3 ES13708044T ES13708044T ES2745208T3 ES 2745208 T3 ES2745208 T3 ES 2745208T3 ES 13708044 T ES13708044 T ES 13708044T ES 13708044 T ES13708044 T ES 13708044T ES 2745208 T3 ES2745208 T3 ES 2745208T3
Authority
ES
Spain
Prior art keywords
cells
cholesterol
hdl
nanostructure
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13708044T
Other languages
English (en)
Spanish (es)
Inventor
C Thaxton
Marina Damiano
Heng Zhang
Kaylin Mcmahon
Shuo Yang
Leo Gordon
Amareshwar Singh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Application granted granted Critical
Publication of ES2745208T3 publication Critical patent/ES2745208T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ceramic Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
ES13708044T 2012-02-22 2013-02-22 Nanoestructuras para tratar cánceres Active ES2745208T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601706P 2012-02-22 2012-02-22
PCT/US2013/027431 WO2013126776A1 (en) 2012-02-22 2013-02-22 Nanostructures for treating cancers and other conditions

Publications (1)

Publication Number Publication Date
ES2745208T3 true ES2745208T3 (es) 2020-02-28

Family

ID=47833440

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13708044T Active ES2745208T3 (es) 2012-02-22 2013-02-22 Nanoestructuras para tratar cánceres

Country Status (11)

Country Link
US (1) US20150064255A1 (enExample)
EP (2) EP3597209A1 (enExample)
JP (1) JP2015513543A (enExample)
KR (1) KR20140123597A (enExample)
CN (1) CN104244965A (enExample)
AU (1) AU2013222238A1 (enExample)
CA (1) CA2865279C (enExample)
ES (1) ES2745208T3 (enExample)
IN (1) IN2014DN07888A (enExample)
MX (1) MX2014010161A (enExample)
WO (1) WO2013126776A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5204646B2 (ja) 2005-04-25 2013-06-05 マサチューセッツ インスティテュート オブ テクノロジー 止血および他の生理学的活性を促進するための組成物および方法
ES2673947T3 (es) 2006-04-25 2018-06-26 Massachusetts Institute Of Technology Composiciones y métodos para afectar al movimiento de contaminantes, líquidos corporales u otras entidades y/o afectar a otras condiciones fisiológicas
CN102036652B (zh) 2008-04-25 2016-04-13 西北大学 适于螯合胆甾醇的纳米结构
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
WO2016011049A2 (en) * 2014-07-14 2016-01-21 Schwendeman Anna Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2016057549A1 (en) 2014-10-06 2016-04-14 Aurasense Therapeutics, Llc Anti-tnf compounds
US10517924B2 (en) * 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
WO2016123365A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2020154705A1 (en) * 2019-01-24 2020-07-30 Northwestern University High-density lipoprotein mimetic nanoparticles using lipid conjugated core scaffolds
JP2022529506A (ja) * 2019-04-26 2022-06-22 ノースウェスタン ユニバーシティ 眼の治療のための高密度リポタンパク質ナノ粒子およびｒｎａテンプレート化リポタンパク質粒子
US20220218788A1 (en) * 2019-05-10 2022-07-14 Northwestern University Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses
US20220331445A1 (en) * 2019-09-18 2022-10-20 Northwestern University High density lipoprotein-like nanoparticles as inducers of ferroptosis in cancer
CN112569207A (zh) * 2019-09-30 2021-03-30 复旦大学 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途
WO2023243865A1 (ko) * 2022-06-13 2023-12-21 (주) 멥스젠 약물전달용 재구축 고밀도 지단백 나노입자

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007210034A1 (en) * 2006-01-26 2007-08-09 University Of Massachusetts RNA silencing agents for use in therapy and nanotransporters for efficient delivery of same
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles
CN102036652B (zh) 2008-04-25 2016-04-13 西北大学 适于螯合胆甾醇的纳米结构
US20130034599A1 (en) * 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities

Also Published As

Publication number Publication date
CN104244965A (zh) 2014-12-24
JP2015513543A (ja) 2015-05-14
EP2817024B1 (en) 2019-07-10
EP3597209A1 (en) 2020-01-22
IN2014DN07888A (enExample) 2015-04-24
KR20140123597A (ko) 2014-10-22
WO2013126776A1 (en) 2013-08-29
MX2014010161A (es) 2015-03-09
US20150064255A1 (en) 2015-03-05
AU2013222238A1 (en) 2014-09-18
EP2817024A1 (en) 2014-12-31
CA2865279C (en) 2023-04-25
CA2865279A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
ES2745208T3 (es) Nanoestructuras para tratar cánceres
Cui et al. Immune exosomes loading self-assembled nanomicelles traverse the blood–brain barrier for chemo-immunotherapy against glioblastoma
KR102585143B1 (ko) 폴리글루타메이트화 항엽산 및 이의 용도
ES2905498T3 (es) Medicamento con afinidad encapsulado en liposoma
Meng et al. Two-wave nanotherapy to target the stroma and optimize gemcitabine delivery to a human pancreatic cancer model in mice
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
Ding et al. Improvement of stability and efficacy of C16Y therapeutic peptide via molecular self-assembly into tumor-responsive nanoformulation
US20230172955A1 (en) Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
Li et al. B16F10 cell membrane-based nanovesicles for melanoma therapy are superior to hyaluronic acid-modified nanocarriers
Hu et al. Treatment of lung cancer by peptide-modified liposomal irinotecan endowed with tumor penetration and NF-κB inhibitory activities
González-Rubio et al. Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy
Chen et al. Inhalable biomimetic polyunsaturated fatty acid-based nanoreactors for peroxynitrite-augmented ferroptosis potentiate radiotherapy in lung cancer
US20220118116A1 (en) Adhesive/adsorption switch on nanoparticles to increase tumor uptake and delay tumor clearance
Zhan et al. LPC-engineered liposomes activate transcytosis for paclitaxel brain delivery and potentiation of TTFields/TMZ via TALECT regimen in glioblastoma
Antonio Polysaccharides as stabilizing and coating agents of polymeric nanocarriers for chemotherapeutics delivery
Linton Nanoparticle-Mediated Communication in the Pancreatic Tumor Microenvironment
BR112019002495B1 (pt) Composição lipossomal peguilada de antifolatos poliglutamatados, seu uso e método de preparação
Daza A" Trojan horse" strategy to reverse drug-resistance in brain tumors
BR122024017509B1 (pt) Composições lipossomais de antifolatos poliglutamatados dglutamil, seu uso e método de preparação
BR112019002497B1 (pt) Composições lipossomais de antifolatos poliglutamatados alfa, seu uso e método de preparação